The use of artificial beta cell in diagnosis and treatment of insulinoma.
The glucose-controlled insulin infusion system (GCIIS), the socalled artificial beta-cell, is an important and useful device for detecting and treating hypoglycemic reactions. The dangers of several diagnostic tests such as the tolbutamide or the insulin response test may successfully be avoided. Patients suffering from severe hypoglycemia are kept in normoglycemia by the feedback-controlled dextrose infusion before and during operation.
D007516:Adenoma, Islet Cell / Q000175:diagnosis / Q000188:drug therapy*; D000328:Adult; D001187:Artificial Organs; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D005246:Feedback; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood / Q000627:therapeutic use*; D007515:Islets of Langerhans / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D014044:Tolbutamide
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D014044:Tolbutamide